Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Combination treatment concerns patients with advanced endometrial carcinoma who progressed on prior systemic treatment and whose tumours are not MSI-H or dMMR
Doxolipad, a hybrid medicine, contains the active substance doxorubicin
The next research and innovation framework programme
PURE findings reflect transition in the predominant causes of deaths in middle-age
The review was triggered by data from several studies showing a higher number of skin cancer cases in patients using a gel for treating actinic keratosis
Third international consensus meeting-based guidelines
Findings from an individual participant meta-analysis of the worldwide epidemiological evidence
Strategies to minimise and manage cardiovascular risk are needed for the growing population of cancer survivors
The study also looked at applications for which the two agencies had different outcomes
Resistance mediated by genomic alterations implicated in the MAPK pathway described
Evidence for efficacy is based on results from the JAKARTA study
It also approvesentrectinibfor the treatment of ROS1-positive metastatic NSCLC in adults
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
